Therefore, if reproducibility is not improved significantly, our data may support that T-DXd is offered to all patients with metastatic HER2-negative BC, rather than to HER2-low patients alone, given the high efficacy of T-DXd reported by Modi et al. [2]. Here, ERBB2 is linked to breast cancer.